FAS triggers ERK activation and increased the transcriptional activity of JAG1/NOTCH signaling components, suggesting that FAS serves as a novel transcriptional activator of the NOTCH signaling pathway and that apoptosis resistance in OSCC may allow residual cancer cells to remain, causing treatment failure and recurrence. Here, FAS is linked to cancer.